For example, targeting EGFR with erlotinib (Tarceva, Genentech) induces vascular normalization by reducing the expression of hypoxia-inducible factor-1α (HIF-1α) and VEGF in head and neck squamous cell carcinoma (HNSCC) xenograft models80. Here, VEGFA is linked to head and neck squamous cell carcinoma.